Item 8.01. Other Events.
On June 29, 2020, United Therapeutics Corporation announced that it has entered
into an amendment extending the term of its exclusive license agreement with Eli
Lilly and Company ("Lilly") covering the U.S. marketing, promotion, and sale of
Adcirca® (tadalafil) tablets through December 31, 2023. Under the agreement,
Lilly granted United Therapeutics an exclusive license for the right to develop,
market, promote and commercialize Adcirca for the treatment of pulmonary
hypertension in the United States. The agreement was previously set to expire on
December 31, 2020. Other terms of the license agreement remain the same.
ADCIRCA is a registered trademark of Eli Lilly and Company.
Item 9.01. Exhibits
(d) Exhibits
Exhibit No. Description of Exhibit
104 The cover page from this Current Report on Form 8-K, formatted in
Inline XBRL
2
© Edgar Online, source Glimpses